Solid Biosciences Inc
SLDB7.000USD
+0.170+2.49%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
542.45MCap. mercado
PérdidaP/E TTM
Más Datos de Solid Biosciences Inc Compañía
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Información de la empresa
Símbolo de cotizaciónSLDB
Nombre de la empresaSolid Biosciences Inc
Fecha de salida a bolsaJan 26, 2018
Director ejecutivoMr. Alexander (Bo) Cumbo
Número de empleados100
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 26
Dirección500 Rutherford Avenue
CiudadCHARLESTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02129
Teléfono16173374680
Sitio Webhttps://www.solidbio.com/
Símbolo de cotizaciónSLDB
Fecha de salida a bolsaJan 26, 2018
Director ejecutivoMr. Alexander (Bo) Cumbo
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
13.23K
+51.52%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+169.09%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
Desglose de ingresos
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
15.36%
Bain Capital Life Sciences Investors, LLC
10.21%
Invus Public Equities Advisors, LLC
9.57%
Adage Capital Management, L.P.
8.68%
Commodore Capital LP
7.51%
Other
48.67%
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
15.36%
Bain Capital Life Sciences Investors, LLC
10.21%
Invus Public Equities Advisors, LLC
9.57%
Adage Capital Management, L.P.
8.68%
Commodore Capital LP
7.51%
Other
48.67%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
32.52%
Hedge Fund
31.63%
Private Equity
15.36%
Investment Advisor/Hedge Fund
13.19%
Venture Capital
8.97%
Research Firm
0.87%
Individual Investor
0.56%
Bank and Trust
0.04%
Family Office
0.01%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
235
79.94M
103.13%
+26.28M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
2023Q2
203
16.54M
84.41%
-1.08M
2023Q1
234
16.00M
82.14%
-1.37M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
11.91M
15.36%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.21%
+2.88M
+57.15%
Mar 31, 2025
Invus Public Equities Advisors, LLC
7.42M
9.57%
+3.67M
+97.81%
Mar 31, 2025
Adage Capital Management, L.P.
6.73M
8.68%
+4.98M
+284.96%
Mar 31, 2025
Commodore Capital LP
5.83M
7.51%
--
--
Mar 31, 2025
RA Capital Management, LP
4.33M
5.59%
+90.74K
+2.14%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.52M
4.54%
+3.47M
+7432.14%
Mar 31, 2025
VR Adviser, LLC
2.48M
3.2%
+2.48M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.46M
3.17%
+1.06M
+75.59%
Mar 31, 2025
Redmile Group, LLC
2.02M
2.6%
+1.40M
+228.19%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
0.67%
Tema Neuroscience and Mental Health ETF
0.29%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción0.67%
Tema Neuroscience and Mental Health ETF
Proporción0.29%
iShares Micro-Cap ETF
Proporción0.07%
ProShares Ultra Nasdaq Biotechnology
Proporción0.04%
Invesco Nasdaq Biotechnology ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.03%
iShares Russell 2000 Value ETF
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Fecha
Tipo
Relación
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
Oct 27, 2022
Merger
15<1
